Short Interest in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Expands By 69.4%

Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) was the target of a significant increase in short interest during the month of February. As of February 27th, there was short interest totaling 19,055 shares, an increase of 69.4% from the February 12th total of 11,249 shares. Currently, 0.4% of the company’s stock are short sold. Based on an average daily trading volume, of 9,298 shares, the short-interest ratio is currently 2.0 days. Based on an average daily trading volume, of 9,298 shares, the short-interest ratio is currently 2.0 days. Currently, 0.4% of the company’s stock are short sold.

Alterity Therapeutics Price Performance

Shares of NASDAQ:ATHE traded up $0.01 on Friday, hitting $3.56. The company had a trading volume of 1,530 shares, compared to its average volume of 11,798. The stock has a 50 day moving average price of $3.39 and a 200 day moving average price of $3.82. Alterity Therapeutics has a 1-year low of $2.52 and a 1-year high of $7.00.

Alterity Therapeutics (NASDAQ:ATHE) last announced its earnings results on Friday, January 30th. The company reported ($0.18) EPS for the quarter. Equities analysts expect that Alterity Therapeutics will post -0.34 earnings per share for the current year.

Wall Street Analyst Weigh In

ATHE has been the subject of a number of analyst reports. Canaccord Genuity Group began coverage on shares of Alterity Therapeutics in a research report on Wednesday, December 17th. They issued a “speculative buy” rating for the company. Zacks Research upgraded shares of Alterity Therapeutics to a “hold” rating in a research note on Thursday, February 12th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Alterity Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold”.

Hedge Funds Weigh In On Alterity Therapeutics

Large investors have recently made changes to their positions in the company. Twin Lakes Capital Management LLC boosted its stake in Alterity Therapeutics by 2,250.3% in the 3rd quarter. Twin Lakes Capital Management LLC now owns 139,258 shares of the company’s stock valued at $524,000 after purchasing an additional 133,333 shares during the period. HB Wealth Management LLC acquired a new stake in shares of Alterity Therapeutics during the third quarter worth $220,000. Citadel Advisors LLC acquired a new stake in shares of Alterity Therapeutics during the third quarter worth $83,000. Finally, Greenleaf Trust boosted its position in shares of Alterity Therapeutics by 88.2% in the third quarter. Greenleaf Trust now owns 32,000 shares of the company’s stock valued at $120,000 after acquiring an additional 15,000 shares during the period. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.